Disclaimers

This confidential presentation has been prepared by Varianz Corp. and Varianz Bio Lab S.A.S (collectively “the Company” or
“Varianz”). This presentation and the material contained herein are confidential and are not to be disclosed to the public. This
presentation is for informational purposes only and may not be reproduced or distributed to any other person or published,
in whole or part, for any purpose whatsoever. This presentation does not constitute a general advertisement or general
solicitation or an offer to sell or a solicitation to buy any securities of the Company in any jurisdiction. Such an offer can only
be made by prospectus or other authorized offering document. This presentation and materials or fact of their distribution or
communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment
decision whatsoever in relation thereto. No securities commission or similar authority in Canada or any other jurisdiction has
in any way passed upon the adequacy or accuracy of the information contained in this presentation. Readers of this
presentation should pay particular attention to the information under the headings “Cautionary Note Regarding
Forward-Looking Information” and “Risk Factors”.

By their acceptance of this presentation, recipients agree that they will not transmit, reproduce or make available to any
person this presentation or any of the information contained herein. Some information in this presentation describes the
Company’s business plan, only including certain assets and relationships held and timing of future events (for example,
commencement of operations and the execution dates of material partnership and commercial agreements for the
international distribution of the Company’s products).
Cautionary Note Regarding Forward-Looking Information
Certain information set forth in this presentation contains “forward‐looking statements” and “forward‐looking information” within the meaning of applicable Canadian and United States securities legislation (referred to herein
as forward‐looking statements). Except for statements of historical fact, certain information contained herein constitutes forward‐looking statements which includes, but is not limited to, statements related to activities, events
or developments that the Company expects or anticipates will or may occur in the future, statements related to the Company’s business strategy, objectives and goals, and management’s assessment of future plans and opera-
tions which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements are often identified by the use of words such as “may”, “will”,
“could”, “would”, “anticipate”, “believe”, “expect”, “intend”, “potential”, “estimate”, “budget”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions. Forward-looking statements are based on a number of factors
and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause
the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In this presentation, forward-looking statements relate to, among other things, the
Company’s strategies and objectives, future expansion plans under consideration, entering into proposed commercial agreements to develop and advance the Company’s business interests, the estimated cost of production
for the Company’s products, the expected value of the global medicinal cannabis market, market growth and size, future revenues, targeted EBITDA and profits, proposed use of the Company’s funds, expected timing and
receipt of necessary government licensing and approvals, ability to scale the Company’s production model, execution of distribution strategy and forecasts of the number of product lines and sales.

Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this presentation is intended to be nor may be construed as a profit forecast.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking
statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or
achievements expressed or implied by such forward-looking statements. Such factors, among other, include: expected timelines for business acquisition and launches; proposed use of cash on hand for the Company’s capital
and other expenditures; generating and finalizing contractual arrangements on terms favorable to the Company or at all; the ability to achieve product milestones in order to satisfy customer demands and deliveries prior to the
execution of definitive customer contracts; market acceptance and adoption of the Company’s business plan and the ability to specifically tailor the Company’s platform to meet the demands of prospective customers; the abil-
ity to modify, enhance and adjust business plans to meet the demands of current and prospective customers; market growth and size; re-allocation of resources to meet customer demands; Company strategies and objectives;
changes to pricing of the Company’s services; forecast of number of product lines and sales; commencement of new operations and plans for expansion; the inability for the Company to execute its corporate strategy as de-
scribed in this presentation or at all; risks related to partnership or other joint operations; regulatory changes; availability or integration of personnel, materials and equipment; inability to recruit or retain management and key per-
sonnel; changes to the composition of the board of directors and management team; capital requirements, operating risks and technological risks associated with the operations or an expansion of the operations of the Compa-
ny; fluctuations in the currency markets; changes in interest rates; disruption to the credit markets and delays in obtaining financing; inflationary pressures; adverse changes to market, political and general economic conditions
or laws, rules and regulations applicable to the Company; regulatory changes or actions that may alter or prohibit operations of companies engaged in cannabis; the Company’s operations and profitability may be adversely
affected by competition from other cannabis companies; and factors discussed under the heading “Risk Factors” in this presentation.

Cautionary Note Regarding Future-Oriented Financial Information

To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being
provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-orient-
ed financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks
set out above under the heading “Cautionary Note Regarding Forward Looking Information”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and,
as a result, the Company’s revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indica-
tion of the Company’s actual financial position or results of operations.

Third Party Information

This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Com-
pany has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying
assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information.
Risk Factors
– Business Risks
The following list sets out certain risk factors applicable to the Company. The list
of risks out below does not purport to be an exhaustive list of the risks applicable
to the Company. Additional risks and uncertainties not presently known to the
Company or that may currently be deemed immaterial could have a substantial
adverse effect on the Company’s business, financial condition and prospects.

Regulatory risks are inherent to the Company

Limited operating history Risk Factors
Liquidity and requirement for additional financing
Regulatory requirements – Risks Related to Companies Operating in Colombia
Permits and licenses
Future acquisitions or dispositions Operational risks
Forward-looking information, future-oriented financial information and financial out-
looks may prove inaccurate
Inflation in Colombia
Ability to generate profits Operations in Spanish
Management of growth
Limited management experience
Enforcement of judgments
Reliance on a single jurisdiction
No guarantee on the use of available funds by the Company
Regulatory changes may result in extraordinary, non-recurring expenses
Ability to grow and sustain market share
Potential conflicts of interest may arise
Reliance on key personnel
Global financial conditions
Increased competition
Constraints on marketing products
Environmental regulations and risks
Risks inherent in an agricultural business
Ability to establish and maintain bank accounts
Energy costs
Security and privacy breaches
Insurance coverage
Dependence on suppliers
Intellectual property concerns
Product liability
Product recalls
Unfavorable publicity or consumer perception
We are a company focused on the medicinal cannabis
industry, with headquarters in Bogotá, Colombia. Varianz
intends to establish a organic agricultural operation, to control
a broad-scope value chain process from planting to
processing, allowing us to obtain a wide portfolio of high
quality, standardized cannabis oil products with rich CBD
content.
Mission
We are committed to working positively with our
stakeholders to develop innovative services and
solutions for the cannabis industry through product
innovation and strategic collaboration with leading
institutions and industry producers around the world.

Vision
Motivated by our passion in the cannabis industry, our
vision is to be world leaders in the supply of medicinal
cannabis oil extracts. To achieve our vision we are
committed to maintaining the best quality standards and
delivering positive product experiences.
Colombia
as a market
Opportunity
ESTABLISHED AGRICULTURAL INDUSTRY
Colombia supplies 70% of the cut flowers sold in Canada and the US and engages in other well-developed agricultural processes.
OPTIMAL CONDITIONS OF GROWTH
A consistent 12 hour light cycle, with powerful equatorial radiation, warm temperatures throughout the year,
fertile soil, abundant rain, and ideal humidity.
LOW COST LABOUR
Large agricultural workforce trained to produce high quality botanical goods.

STABLE GOVERNMENT
Transparent and equitable foreign investment regime.

NATIONAL MARKET FOR MEDICINAL CANNABIS

The population in Colombia is 49 million people with a potential emerging market among the growing middle class.

WELL-RECOGNIZED SCIENTIFIC COMMUNITY

Top local universities committed to cannabis research.
 Location
Varianz´s growing and production facilities are located in Flandes, Tolima (144Km from Bogotá).
Currently, the facilities include 20 hectares of agricultural land with natural water sources available.

Bogotá

Flandes
 Location
Advantages
Easy access to property.
Proximity to local airport.
Natural water supply.
Low humidity.
Fertile Soils.
Electricity access.
12 hours cycles of natural light all year.
No known security issues in the region .
All aspects of Varianz´s business and production will be entirely situated on the Flandes
property (farming, research, processing, transformation, manufacturing).

Varianz has leased the initial 20 hectares comprising the Flandes property where the
project is being developed and has options to expand to an additional 200 hecaters at the
same location. Varianz also has a first opportunity to purchase the initial 20 hectares at
competitive market prices.

The climatic conditions of our land are suitable for the proper growth of cannabis plants.
 Already
Moving
As of 2018 we began the construction of our green-
houses and we expect to continue expanding for
the next 4 years.
Licences

Seeds Cultivation Extraction & Cultivation

Production Licences Transformation Licences
Licence (Non-psychoactive) Licence (Psychoactive)
Ministry of Justice Ministry of Health Ministry of Justice
Ministry of Justice

GRANTED GRANTED GRANTED

GRANTED August 2019 October 2019
February 2019 May 2019
 Strategic Pillars
Seeds
Seed Sourcing permit granted.
29 + Strains registered.
Agronomic evaluation unit
permit granted.
Strains registered
10 Strains atatthe
registered the
national cultivar register:
national cultivar.
Expected by Q2 2020.
Extraction
Crops Distribution
Approximately 15,000 sq. ft
Fullyextraction
Toll facilities. (0.14ha)
integratedfacilities
2 different extraction methods.
Agreements with clinics.
A total area of E.U GMP Standards.
2,152,782 sq. ft licensed.
(20ha) ISO 9001 Certification. LOI with EU buyers.
Planned cultivated area in first year:
years:
215,278 sq.ft
107.639 (2ha)
sq. ft (1ha) LOI with national laboratories.
Fast Production Scalability.
400 equipped
Greenhouses by 2023.
 Strategic Pillars Seeds

Permits
Registration Seed Sourcing Unit of Agronomic 29+ strains
As Seed Permit Evaluation Permit 18 Hemp-Low THC

Producer 11 Psychoactive

Agricultural Institute Agricultural Institute Agricultural Institute Agricultural Institute

GRANTED GRANTED GRANTED REGISTERED
March 2019 Strains Registered at
The National Cultivar Register
ICA´S requirements to become a seed
(currently on trials)
producer have been met.
Expected by Q2
4 2020
 Strategic Pillars
Seeds
Seed Sourcing permit granted.
29 + Strains registered.
Agronomic evaluation unit
permit granted.
Strains
10 registered
Strains registeredatatthe
the
national cultivar. register:
national cultivar
Expected by 2Q 2020.
Extraction
Crops Distribution
Approximately 15,000 sq. ft
Fullyextraction
Toll facilities. (0.14ha)
integratedfacilities
2 different extraction methods.
Agreements with clinics.
A total area of E.U GMP Standards.
2,152,782 sq. ft licensed.
(20ha) ISO 9001 Certification. LOI with EU buyers.
Planned cultivated area in first year:
years:
(2ha)
215,278 sq.ft
107.639 sq. ft (1ha) LOI with national laboratories
Fast Production Scalability.
400 equipped
Greenhouses by 2023.
 Strategic Pillars Crops

Project
Schedule
Agricultural Project 1He (5yrs)

Phases 1stArea
Area 2nd Area
Schedule Schedule
(Flandes) (to be leased)

PrePhase
Operative
I 0,3
0,2--ha
1ha Jan 2021
2020 - December
-- 2021
2020 June 2019 - December 2019

Phase I II
Phase 2ha
20ha
0,5
0,8ha
ha
1ha Jan
Jan 2022 --
2021 -- December
December 2022
2021 Jan 2020 - December 2020

Phase
PhaseII III 5ha
21ha
1 ha Jan
Jan 2023 1.5ha 2023
2022 -- December
December 2022 Jan 2021 - December 2021

Phase
PhaseIII IV 5ha
1ha
12
1 ha
ha Jan
Jan 2024 3.5ha 2024
2023 -- December
December 2023 Jan 2022 - December 2022

Phase
PhaseIV V 18ha
9ha
21ha
ha Jan
Jan 2025 5ha
2024 -- December
December 2025
2024 Jan 2023 - December 2023

Total 8,2
3.8
420ha
4ha
ha
ha 10ha

Combined
*Maximum
*20 hectares
licence
licence
20 hectares.
30ha *20 hectare vision
*Option totoexpand
*Options expand to
to an
an additional
additional 200
200 hectares
hectares at the
same location.
 Strategic Pillars

Seeds Extraction

Seed Sourcing permit granted.
29 + Strains registered.
Agronomic evaluation unit
permit granted.
Strains
10 registered atatthe
10 Strains
Strains registered
registered at the
the
national cultivar register:
national
national cultivar.
cultivar.
Expected by 2Q 2020.
Crops Distribution
Approximately 15,000 sq. ft
Fullyextraction
Toll facilities. (0.14ha)
integratedfacilities
2 different extraction methods.
Agreements with clinics.
A total area of E.U GMP Standards.
2,152,782 sq. ft licensed.
(20ha) ISO 9001 Certification. LOI with EU buyers.
Planned cultivated area in first year:
years:
215,278 sq.ft
107.639 (2ha)
sq. ft (1ha) LOI with national laboratories.
Fast Production Scalability.

400 equipped
Greenhouses by 2023.
 Strategic Pillars Extraction

Extraction
Methods
Varianz
Varianzwill
is use
will twoa different
using
use methods forprocess with
toll manufacturing
two different methods for the extraction of the CBD
the extraction of the CBD of Cannabis.
of Cannabis.

CO2 supercritical extraction method

Supercritical Fluid Extraction  (SFE) is the process of separating one
component (the extractant) from another (the matrix) using  supercritical
fluids as the extracting solvent.

The result of these processes is the cannabis oil, which is a concentrate of

all the active pharmaceutical ingredients in the marijuana plant, and is a
dynamic substance that can be transformed into numerous forms for user
consumption.

Ethanol extraction method

Extracting cannabis flowers through distillation is extremely efficient.
Suitable for Warm and Cold Wash methods of extraction, steam distillation,
solvent recovery and spirits distilling. The extractor can be used as a
highly-efficient vacuum oven for dehydrating or decarboxilating.
 Strategic Pillars
Seeds
Seed Sourcing permit granted.
29 + Strains registered.
Agronomic evaluation unit
permit granted.
Strains
10 registered
Strains registeredatatthe
the
national cultivar. register:
national cultivar
Expected by 2Q 2020.
Extraction
Crops Distribution
Approximately 15,000 sq. ft
Fullyextraction
Toll facilities. (0.14ha)
integratedfacilities
2 different extraction methods.
Agreements with clinics.
A total area of E.U GMP Standards.
2,152,782 sq. ft licensed.
(20ha) ISO 9001 Certification. LOI with EU buyers.
Planned cultivated area in first year:
years:
(2ha)
215,278 sq.
107.639 sq.ftft (1ha) LOI with national laboratories.
Fast Production Scalability.
400 equipped
Greenhouses by 2023.
 Strategic Pillars Distribution
Distribution Partners
National International

Sergio Rada & Alexandra Rada Trinciato

Specialized Aesthetic medicine clinic with 30 years of
experience and more than 200,000 patients in Latam.
Executed LOI to provide the clinic with high quality cannabis oil.
Executed LOI for the creation and distribution of cosmetics.
SPV vehicle being structured with Trinciato for a collaborative
partnership to produce CBD infused cosmetic products, with
platform for eventual sales & distribution.

PH Plus
PH PLUS is the leader in production of alkaline water In Colombia with a
pH level of 9.
Expected LOI to provide high quality oil for the production of CBD water.
Expected LOI for the elaboration and distribution of CBD waters.
Arteasan
Currently in negotiations with Artesan to form a joint venture
project to be focused on creating CBD infused beverages.

Lha
Is a Colombian pharmaceutical laboratory specialized in the
development and production of homeopathic medicines for
humans and animals
LOI to provide high quality CBD oil for medicines.
Academic and Government Alliances
Certification And Quality
Management System

EU - Regulation EEC No. 834/2007 of Organic Production Cultivation

Since the beginning our cultivation and post-harvest
USDA - NOP Organic regulation for USA process will be managed pursuant to international
organic regulations. We will focus on maintaining
Canadian Organic Regime - COR sustainable production from balanced and fertile soil
while respecting the natural human impact on the
environment operating as naturally as possible.
ISO 9001: 2015 - Quality Management System

Control Union Medical Cannabis Standard G.A.P. (CUMCS – GAP) , Good Agricultural
Practice (G.A.P.) based on The World Health Organisation (WHO) guidelines on good
agricultural & collection practices (GACP) for medicinal plants - Geneva 2003,
Guidelines of the Dutch Government for Cannabis for Medical Use:  Nederland,
Extraction
December 2002, International Standard for Good Agriculture Practice: GLOBAL Our extraction
Varianz toll facilities have been designed with the
Varianz toll manufacture
manufactureextraction
extractionfacilities
facilitieswill be
will in
be
G.A.P. IFA 4.0 (FV), March 2013 intentions
icompliance
of being
n c o m p l i awith
considered
n c e international
as state
w i t h i n t e rquality
of the art faci-
n a t i o ncertifications.
al quality
lities with the ability to obtain awillvariety of international
EudraLex - Volume 4 - Good Manufacturing Practice (GMP) guidelines This approach
certifications.
quality will approach
This
certifications. allow
This us to control
approach will the
allow us to process
allowcontrol
us to
(GACP) (EMEA/HMPC/246816/2005) the process
throughout
control the thethroughout the
wholethroughout
process whole
value chain value
the and chain
wholeproduceand
value
produce
chain products
andwithproduce with high
products quality standards.
with the high quality
products high quality standards.
ICH Q7A - GMP EU PART II: standards.
Basics requirements for active substances used as starting materials (APIs)

Good manufacturing practices guide for drug products (GUI-0001) -

 Corporate
Governance Policies
Varianz is currently working on the
implementation of the following policies:

Corporate Governance Policies

Operational Policies
Sustainability Policy
Human Talent Policy
Prevention of Money Laundering and Terrorist Financing Policy
Protection and Personal Data Policy
Supply Chain Management and Procurement Policy
Delegation of Authority Policy
Management Team
 Leovigildo Criollo
Cultivation Manager
15+ years of experience in the flower industry. Mr.
Criollo has several years of experience working for
cannabis companies as a technical advisor and has
managed projects for La Santa S.A.S.
Mr. Criollo holds a degree in Agronomic Engineering
from Universidad de los Llanos.
He has acted as an external advisor for multiple
cannabis companies working with medical plants and
their derivative products.
Lina Paola Saavedra
Head of Post - Harvest
20+ years of experience in the agroindustrial sector. Ms.
Saavedra has been working in the flower business most of
her career, in the cannabis industry she has worked as a
Post Harvest Manager in Clever Leaves.
Ms. Saavedra holds a degree in Agroindustrial Engineering
from Universidad de la Sabana, Colombia. Ms. Saavedra
had participated in the implementation of Good
Manufacturing Practices in other companies.
Lorena Acero
Master Grower
6+ years of experience in outdoor and indoor cannabis
cultivation. For 2 years she has been working as the
Master Grower of Varianz agronomical team, applying
her knowledge of her great depth and breadth of
knowledge about the cannabis plant and experience in
plant production.
Ms Acero is the Co-Founder of Ganjah Grow Shop, a
supply and consulting store for cannabis cultivation,
which has an educational approach in which basic
cultivation workshops are taught for beginners and
advanced techniques for people with more experience.
 Growth
Oportunities

• + Cultivation Hectares • Expansion Into New Areas

20H fully licenced in Flandes, Colombia with the Possibility of 200+ Inside Colombia or worlwide.
in the same land.

• Final Product • Extraction Facilities

Commercial Oils, Beauty & Skin Care Products, Beverages, Edibles, EU GMP Extraction facilities in a free trade zone.
veterinary products and more.
Invest in Varianz
Canadian cannabis fully licensed company with operations in Colombia.

Highly experienced team.

Low cost labour and production

29+ proprietary strains registered

Locations with excellent growing conditions.

Fast and scalable growing capacity.

Premium medical-grade cannabis oil extracts. Multiple

Multipleextraction processes
toll extraction will be available.
processes available.

Under Construction
Multiple and future
toll extraction facilitiesavailable.
processes in compliance with GMP standards.

Diversified Product Portfolio (CBD and THC oil, isolates and distillates.)
for further information please contact:

Federico Restrepo Solano Partner & Corporate Director

f.restrepo@qvartzcap.com

Alejandro Jimenez Ramirez

danielbaquero@varianz.co
Daniel Baquero Partner
C.E.O /&Cofouder
New Business Director
+57 3115927899
a.jimenez@qvartzcap.com

www.qvartzcap.com

www.varianz.co info@varianz.co